New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

We are navigating political interference, institutional instability, and growing uncertainty across the cancer research ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

The session follows the American Association for Cancer Research's prior call to action against executive orders that would ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today outlined a framework for a ...

The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

Immunotherapy let some cancer patients with mismatch repair deficient tumors completely avoid surgery, chemo and radiation, a ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Findings demonstrate ATYR2810's anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...